Gate Booster 第 4 期:发帖瓜分 1,500 $USDT
🔹 发布 TradFi 黄金福袋原创内容,可得 15 $USDT,名额有限先到先得
🔹 本期支持 X、YouTube 发布原创内容
🔹 无需复杂操作,流程清晰透明
🔹 流程:申请成为 Booster → 领取任务 → 发布原创内容 → 回链登记 → 等待审核及发奖
📅 任务截止时间:03月20日16:00(UTC+8)
立即领取任务:https://www.gate.com/booster/10028?pid=allPort&ch=KTag1BmC
更多详情:https://www.gate.com/announcements/article/50203
Pfizer Targets Pediatric Ulcerative Colitis With New Etrasimod Trial: What Investors Should Watch
Pfizer Inc. is initiating a Phase 2 trial for its drug etrasimod in children with moderate to severe ulcerative colitis, aiming to evaluate its efficacy and safety in this young patient population. The open-label, single-arm study will have participants treated for up to 52 weeks with an option for a long-term extension. This move expands etrasimod’s potential market and positions Pfizer against competitors like AbbVie and Johnson & Johnson in the inflammatory bowel disease space.